Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 93

1.

Direct Renin inhibitor: aliskiren in chronic kidney disease.

Morishita Y, Kusano E.

Nephrourol Mon. 2013 Winter;5(1):668-72. doi: 10.5812/numonthly.3679. Epub 2012 Dec 15.

2.
3.

Effects of aliskiren on blood pressure and the predictive biomarkers for cardiovascular disease in hemodialysis-dependent chronic kidney disease patients with hypertension.

Morishita Y, Hanawa S, Chinda J, Iimura O, Tsunematsu S, Kusano E.

Hypertens Res. 2011 Mar;34(3):308-13. doi: 10.1038/hr.2010.238. Epub 2010 Dec 2.

PMID:
21124333
4.

Renin inhibition ameliorates renal damage through prominent suppression of both angiotensin I and II in human renin angiotensinogen transgenic mice with high salt loading.

Yoshida S, Ishizawa K, Ayuzawa N, Ueda K, Takeuchi M, Kawarazaki W, Fujita T, Nagase M.

Clin Exp Nephrol. 2014 Aug;18(4):593-9. doi: 10.1007/s10157-013-0893-6. Epub 2013 Oct 24.

PMID:
24154707
5.
6.

[Direct renin inhibitor aliskiren in the treatment of cardiovascular and renal diseases].

Horký K.

Vnitr Lek. 2010 Feb;56(2):120-6. Review. Czech.

PMID:
20329582
7.

Inhibition of the renin angiotensin aldosterone system: focus on aliskiren.

Rao MS.

J Assoc Physicians India. 2010 Feb;58:102-8. Review.

PMID:
20653151
8.

Is there a future for direct renin inhibitors?

Chaudhary K, Nistala R, Whaley-Connell A.

Expert Opin Investig Drugs. 2010 May;19(5):653-61. doi: 10.1517/13543781003781906. Review.

PMID:
20380486
9.
10.

Effect of add-on direct renin inhibitor aliskiren in patients with non-diabetes related chronic kidney disease.

Li SY, Chen YT, Yang WC, Tarng DC, Lin CC, Yang CY, Liu WS.

BMC Nephrol. 2012 Aug 23;13:89. doi: 10.1186/1471-2369-13-89.

11.

New insights into the renoprotective actions of the renin inhibitor aliskiren in experimental renal disease.

Feldman DL.

Hypertens Res. 2010 Apr;33(4):279-87. doi: 10.1038/hr.2010.19. Epub 2010 Mar 5. Review.

PMID:
20203685
12.

Direct renin inhibition--a promising strategy for renal protection?

Lizakowski S, Tylicki L, Rutkowski B.

Med Sci Monit. 2013 Jun 12;19:451-7. doi: 10.12659/MSM.883949. Review.

13.

Aliskiren suppresses the renin-angiotensin-aldosterone system and reduces blood pressure and albuminuria in elderly chronic kidney disease patients with hypertension.

Morishita Y, Yasui T, Numata A, Onishi A, Ishibashi K, Kusano E.

Int J Nephrol Renovasc Dis. 2012;5:125-33. doi: 10.2147/IJNRD.S36451. Epub 2012 Sep 21.

14.

Direct renin inhibition: focus on aliskiren.

Pool JL.

J Manag Care Pharm. 2007 Oct;13(8 Suppl B):21-33. Review.

15.
16.

Antihypertensive Efficacy of the Direct Renin Inhibitor Aliskiren as Add-on Therapy in Patients with Poorly Controlled Hypertension.

Tani S, Kushiro T, Takahashi A, Kawamata H, Ohkubo K, Nagao K, Hirayama A.

Intern Med. 2016;55(5):427-35. doi: 10.2169/internalmedicine.55.5629. Epub 2016 Mar 1.

17.

Aliskiren and valsartan combination therapy for the management of hypertension.

Epstein BJ.

Vasc Health Risk Manag. 2010 Sep 7;6:711-22. Review.

18.

Aliskiren, a direct renin inhibitor, in clinical practice: a new approach in the treatment of hypertension.

Moutzouri E, Florentin M, Elisaf MS, Mikhailidis DP, Liberopoulos EN.

Curr Vasc Pharmacol. 2010 May;8(3):344-62. Review.

PMID:
20180771
19.

Current strategies to achieve further cardiac and renal protection through enhanced renin-angiotensin-aldosterone system inhibition.

Alfie J, Aparicio LS, Waisman GD.

Rev Recent Clin Trials. 2011 May;6(2):134-46. Review.

PMID:
21241234
20.

Aliskiren: An orally active renin inhibitor.

Wal P, Wal A, Rai AK, Dixit A.

J Pharm Bioallied Sci. 2011 Apr;3(2):189-93. doi: 10.4103/0975-7406.80764.

Supplemental Content

Support Center